1
One
Year Post Exclusivity Adverse Event Review as Mandated by the
Best Pharmaceuticals for Children Act
Presented at the
Psychopharmacologic Drugs Advisory Committee
& Pediatric Subcommittee of the Anti-Infective Drugs Advisory Committee Meeting
February 2, 2004
Best Pharmaceuticals for Children Act
Presented at the
Psychopharmacologic Drugs Advisory Committee
& Pediatric Subcommittee of the Anti-Infective Drugs Advisory Committee Meeting
February 2, 2004
Solomon Iyasu, MD, MPH
Hari Cheryl Sachs, MD, FAAP
Division of Pediatric Drug DevelopmentCenter for Drug Evaluation and Research
Food and Drug Administration
